Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
$1.18
$1.84
$0.39
$18.00
$5.59M3.523,627 shs142 shs
Dynatronics Co. stock logo
DYNT
Dynatronics
$0.55
-3.5%
$0.47
$0.37
$1.51
$2.81M0.45368,027 shs66,628 shs
Sigyn Therapeutics, Inc. stock logo
SIGY
Sigyn Therapeutics
$6.34
+10.3%
$5.30
$2.08
$12.80
$7.74M-1.68276 shs200 shs
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
0.00%+12.38%-34.99%-69.74%-60.67%
Dynatronics Co. stock logo
DYNT
Dynatronics
-3.56%+4.30%+24.03%+8.59%-61.73%
Sigyn Therapeutics, Inc. stock logo
SIGY
Sigyn Therapeutics
+10.26%+10.26%+40.89%+5,655.79%+4,824.27%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
0.8203 of 5 stars
3.03.00.00.00.60.00.6
Sigyn Therapeutics, Inc. stock logo
SIGY
Sigyn Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/AN/AN/AN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
2.00
Hold$3.80584.81% Upside
Sigyn Therapeutics, Inc. stock logo
SIGY
Sigyn Therapeutics
N/AN/AN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
$80K69.92N/AN/A($2.43) per share-0.49
Dynatronics Co. stock logo
DYNT
Dynatronics
$35.18M0.08N/AN/A$2.19 per share0.25
Sigyn Therapeutics, Inc. stock logo
SIGY
Sigyn Therapeutics
N/AN/AN/AN/A($2.80) per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
-$6.98MN/A0.00N/A-6,809.45%N/A-386.74%5/20/2024 (Estimated)
Dynatronics Co. stock logo
DYNT
Dynatronics
-$4.97M-$1.38N/AN/A-14.13%-54.88%-16.14%5/9/2024 (Estimated)
Sigyn Therapeutics, Inc. stock logo
SIGY
Sigyn Therapeutics
-$4.15M-$3.60N/AN/AN/AN/A-958.06%N/A

Latest ARTH, SIGY, and DYNT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/20/2024Q1 2024
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/A-$0.57-$0.57-$0.57N/A$0.05 million
2/7/2024Q2 2024
Dynatronics Co. stock logo
DYNT
Dynatronics
N/A-$0.27-$0.27-$0.27N/A$8.15 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/AN/AN/AN/AN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
N/AN/AN/AN/AN/A
Sigyn Therapeutics, Inc. stock logo
SIGY
Sigyn Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/A
0.16
0.04
Dynatronics Co. stock logo
DYNT
Dynatronics
0.21
1.41
0.67
Sigyn Therapeutics, Inc. stock logo
SIGY
Sigyn Therapeutics
N/A
0.03
0.02

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
6.91%
Dynatronics Co. stock logo
DYNT
Dynatronics
4.18%
Sigyn Therapeutics, Inc. stock logo
SIGY
Sigyn Therapeutics
10.01%

Insider Ownership

CompanyInsider Ownership
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
4.50%
Dynatronics Co. stock logo
DYNT
Dynatronics
9.10%
Sigyn Therapeutics, Inc. stock logo
SIGY
Sigyn Therapeutics
78.46%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
84.74 million4.53 millionNot Optionable
Dynatronics Co. stock logo
DYNT
Dynatronics
1544.88 million4.44 millionNot Optionable
Sigyn Therapeutics, Inc. stock logo
SIGY
Sigyn Therapeutics
51.22 million264,000Not Optionable

ARTH, SIGY, and DYNT Headlines

SourceHeadline
Critical Survey: Quipt Home Medical (NASDAQ:QIPT) and Sigyn Therapeutics (OTCMKTS:SIGY)Critical Survey: Quipt Home Medical (NASDAQ:QIPT) and Sigyn Therapeutics (OTCMKTS:SIGY)
americanbankingnews.com - April 22 at 1:26 AM
Sigyn Therapeutics™ to Present at Tomorrow’s Emerging Growth ConferenceSigyn Therapeutics™ to Present at Tomorrow’s Emerging Growth Conference
finance.yahoo.com - March 5 at 1:21 PM
Sigyn Therapeutics to Present at Tomorrows Emerging Growth ConferenceSigyn Therapeutics to Present at Tomorrow's Emerging Growth Conference
finance.yahoo.com - March 5 at 1:21 PM
Sigyn Therapeutics™ to Present at Tomorrows Emerging Growth ConferenceSigyn Therapeutics™ to Present at Tomorrow's Emerging Growth Conference
globenewswire.com - March 5 at 9:00 AM
Sigyn Therapeutics™ Announces Filing of 2023 Annual Report on SEC Form 10-KSigyn Therapeutics™ Announces Filing of 2023 Annual Report on SEC Form 10-K
globenewswire.com - February 21 at 8:45 AM
Sigyn Therapeutics, Inc.: Sigyn Therapeutics Completes Reverse Stock SplitSigyn Therapeutics, Inc.: Sigyn Therapeutics Completes Reverse Stock Split
finanznachrichten.de - February 3 at 12:29 AM
Sigyn Therapeutics Announces 1-for-40 Reverse Stock SplitSigyn Therapeutics Announces 1-for-40 Reverse Stock Split
msn.com - February 2 at 12:35 AM
Sigyn Therapeutics Completes Reverse Stock SplitSigyn Therapeutics Completes Reverse Stock Split
finance.yahoo.com - February 1 at 7:34 PM
Sigyn Therapeutics, Inc.: Sigyn Therapeutics Announces Reverse Stock SplitSigyn Therapeutics, Inc.: Sigyn Therapeutics Announces Reverse Stock Split
finanznachrichten.de - January 30 at 1:10 PM
Sigyn Therapeutics, Inc.: Sigyn Therapeutics Releases Letter to ShareholdersSigyn Therapeutics, Inc.: Sigyn Therapeutics Releases Letter to Shareholders
finanznachrichten.de - January 30 at 1:10 PM
EQS-News: Sigyn Therapeutics Announces Reverse Stock SplitEQS-News: Sigyn Therapeutics Announces Reverse Stock Split
markets.businessinsider.com - January 30 at 1:10 PM
Sigyn Therapeutics Announces Reverse Stock SplitSigyn Therapeutics Announces Reverse Stock Split
finance.yahoo.com - January 30 at 1:10 PM
Sigyn Therapeutics Releases Letter to ShareholdersSigyn Therapeutics Releases Letter to Shareholders
finance.yahoo.com - January 4 at 10:04 AM
Sigyn Therapeutics, Inc.: Sigyn Therapeutics Announces Appointment of Jerry DeCiccio as Chief Financial OfficerSigyn Therapeutics, Inc.: Sigyn Therapeutics Announces Appointment of Jerry DeCiccio as Chief Financial Officer
finanznachrichten.de - December 12 at 1:44 PM
Sigyn Therapeutics appoints Jerry DeCiccio as finance chiefSigyn Therapeutics appoints Jerry DeCiccio as finance chief
msn.com - December 12 at 1:44 PM
Sigyn Therapeutics Announces Appointment of Jerry DeCiccio as Chief Financial OfficerSigyn Therapeutics Announces Appointment of Jerry DeCiccio as Chief Financial Officer
finance.yahoo.com - December 12 at 8:44 AM
Sigyn Therapeutics, Inc.: Sigyn Therapeutics Reports Third Quarter 2023 Financial ResultsSigyn Therapeutics, Inc.: Sigyn Therapeutics Reports Third Quarter 2023 Financial Results
finanznachrichten.de - November 15 at 9:27 PM
Sigyn Therapeutics Inc GAAP EPS of -$0.02Sigyn Therapeutics Inc GAAP EPS of -$0.02
msn.com - November 15 at 11:26 AM
Sigyn Therapeutics Reports Third Quarter 2023 Financial ResultsSigyn Therapeutics Reports Third Quarter 2023 Financial Results
finance.yahoo.com - November 14 at 5:42 PM
Sigyn Therapeutics™ Discloses PCT Patent Submission to Enhance Chemotherapy Delivery and Reduce Cancer Treatment ToxicitySigyn Therapeutics™ Discloses PCT Patent Submission to Enhance Chemotherapy Delivery and Reduce Cancer Treatment Toxicity
finance.yahoo.com - October 4 at 10:21 AM
Sigyn Therapeutics to Present at Today’s Emerging Growth Conference and Tomorrow at the National Investment Bankers Association ConferenceSigyn Therapeutics to Present at Today’s Emerging Growth Conference and Tomorrow at the National Investment Bankers Association Conference
finance.yahoo.com - September 15 at 8:19 AM
FDA Authorizes Better Therapeutics Mobile App for Treating Type 2 DiabetesFDA Authorizes Better Therapeutics Mobile App for Treating Type 2 Diabetes
medcitynews.com - July 15 at 6:08 PM
Relay Therapeutics Inc Ordinary SharesRelay Therapeutics Inc Ordinary Shares
morningstar.com - June 23 at 9:00 AM
Beam Therapeutics (NASDAQ: BEAM)Beam Therapeutics (NASDAQ: BEAM)
fool.com - May 22 at 12:19 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Arch Therapeutics logo

Arch Therapeutics

OTCMKTS:ARTH
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.
Dynatronics logo

Dynatronics

NASDAQ:DYNT
Dynatronics Corporation, a medical device company, designs, manufactures, and sells physical therapy, rehabilitation, orthopedics, pain management, and athletic training products in the United States. The company offers orthopedic soft bracing products include cervical collars, shoulder immobilizers, arm slings, wrist and elbow supports, abdominal and lumbosacral supports, maternity supports, knee immobilizers and supports, ankle walkers and supports, plantar fasciitis splints, and cold therapy products. It also offers physical therapy and rehabilitation products, which include therapeutic modality devices comprising electrotherapy, ultrasound, phototherapy, traction, hot and cold therapy, and electrodes; and power and manually operated treatment tables, mat platforms, work tables, parallel bars, training stairs, weight racks, and other related equipment. In addition, the company manufactures and distributes clinical supplies, including exercise bands and tubing, lotions and gels, orthopedic bracings, paper products, and other related supplies. It markets its products under the Dynatron, Dynatron Solaris, Dynaheat, BodyIce, Powermatic, Bird & Cronin, Physician's Choice, Hausmann, PROTEAM, and Mammoth brands. The company sells its products to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, hospitals, and retail distributors and equipment manufacturers. It also exports its products in Asia, Latin America, and the Middle East. Dynatronics Corporation was founded in 1979 and is headquartered in Eagan, Minnesota.
Sigyn Therapeutics logo

Sigyn Therapeutics

OTCMKTS:SIGY
Sigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.